Trials / Recruiting
RecruitingNCT06601010
The Value of 68Ga-grazytracer PET in Monitoring Responses to Immunotherapy of Pancreatic Cancer.
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 30 (estimated)
- Sponsor
- Ruijin Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to investigate the value of 68Ga-grazytracer in predicting the efficacy of immunotherapy for pancreatic cancer.
Detailed description
The investigators will number all participants, create a medical record file, and record their basic information (gender, age) as well as contact information and medical history information. All participants will undergo a 68Ga-grazytracer PET/CT after 3 cycles of immunotherapy to evaluate response. The imaging response measurements will be compared with the histopathological or clinical assessment results as gold standard.
Conditions
Timeline
- Start date
- 2024-09-24
- Primary completion
- 2026-07-31
- Completion
- 2027-08-31
- First posted
- 2024-09-19
- Last updated
- 2024-12-11
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06601010. Inclusion in this directory is not an endorsement.